Introduction
Coumarina nticoagulants, also called vitamin Ka ntagonists (VKAs),a re effective in the prevention of venous and arterial thromboembolism (1) .VKAs suppress ther egeneration of the reduced formofvitamin Kbyinhibiting vitamin Kepoxide reductase. The vitamin Kc ycle regenerates reducedv itamin K1 from its epoxide. . Reduced vitamin Kisacofactor for post-translational gamma-carboxylation of glutamic acidresiduesonseveral proteins fornormal haemostasis. This resultsinnegatively charged gamma-carboxyglutamates on factorsII, VII, IX, and X, whichbind to calcium cations and thentoplateletphospholipid membranes. Gamma-carboxylation is also requiredf or the development of othert issues. VKAs also inhibit the gamma-carboxylation of anticoagulant proteins C, S, Z, and osteocalcin. VKAsi nhibition of clotting factor activity is their main pharmacologic effect.This is responsible for VKAsability to inhibit clot formation.
The major side effect of VKAsi sm ajor bleeding,w ith reported incidences of 1.5to5.0 per 100 patient-years (2, 3) . The incidenceofboth bleeding and thromboembolic eventsincreases sharplywith advanced age. Therisk of over-and under-coagulation in patients taking VKAsisassociatedwith drug-VKAs interactions, food-VKAs interactions, and disease-VKAs interactions.Alcoholc onsumption, liverd isease, and other unknown factorsalso influenceoptimal dailydosages. Other inter-individual variationst hat affect predicting optimal dailyd osagesi nclude pharmacogenetic predisposition, age and patient obesity, whichc orresponds to the amount of coumarin anticoagulants requiredfor initiation of therapy (4) (5) (6) . This explains whyoral anticoagulants have asmall therapeutic window, and the stability of anticoagulant therapycan be easilydisturbed.
Both safety (primarily risk of bleeding)and effectiveness of VKAst herapyr elates to blood international normalised ratio (INR) values( 7). Monitoring of INRand dose adjustments of coumarin anticoagulants aref requently required. Futhermore, pharmacogenetics,the fieldofresearch describing the influence of variationsofDNA characteristics on drug response,plays an important roleinthe safety and effectiveness of VKAs.
Warfarin is the VKAs drug of choiceinmost countries. Ye t acenocoumarol and phenprocoumon are used in many European countries, includingThe Netherlands and Germany. Several reviewsand researchpapersonthe pharmacogenetic influences of warfarin are available(8, 9). Comparatively systematic information on the pharmacogenetic influences of acenocoumarol and phenprocoumon is scarce. In this review,wefocus on the pharmacogeneticsofphenprocoumon and acenocoumarol, comparing these drugs with the pharmacogeneticsofwarfarin. We also exploredthese drugs' relevance to therapeutic choices.
We performed the literaturesearch in EMBASE and Medline (PUBMED)from 1995 to June2008. We includedstudieswith originaldataonpharmacogeneticsofphenprocoumon and acenocoumarol. Data from warfarin reviewsand additional relevant papers not included in the cited reviews were alsoi ncluded. Search words and termsi ncluded: pharmacogeneticsa nd/or pharmacogenomics; acenocoumarol;p henprocoumon; CYP2C9 and/or genotype and /or polymorphism;V KORC1; warfarin and review;and coumarin anticoagulants.
Cytochrome P4502C9 and VKORC1 and other genetic variants
CytochromeP 450 (CYP) is ag roupo fh epatic microsomal enzymes thatact as monooxygenases of endobiotics (steroid hormones, fatty acids derivates, and vitamins) and xenobiotics (drugs, pollutants, and carcinogens).The abbreviation CYP,followedb yan umber,ac apitall ettera nd anothern umber (e.g. CYP2D6, CYP3A4, CYP2C9), designates an individual enzyme from this group of monooxygenases. Cytochromes transformlipophilic drugs into moreh ydrophilic metabolites whichfacilitatesfurther elimination and renal excretion.
Thegene CYP2C9 encodes the enzyme CYP2C9, of which about 30 variant alleles have beend escribed.T he most frequentlyo ccurring variant alleles in Caucasians are CYP2C9*2 (CGT>TGT in exon 3) and CYP2C9*3 (ATT>CTT in exon 7) (10).
Thesefactors lead CYP2C9toplayarole in the metabolismof: -C oumarin anticoagulant drugs (warfarin, acenocoumarol, phenprocoumon) -N onsteroidalanti-inflammatorydrugs (NSAIDs) (e.g. diclofenac,i buprofen, lornoxicam, celecoxib, flurbiprofen, naproxen) -S ulfonylureas (e.g. tolbutamide, glipizide) -P henytoin Inhibitors of CYP2C9 include some SSRI type antidepressants (e.g. fluoxetine,fluvoxamine), amiodarone, benzbromarone, cotrimoxazol,cimetidine and antimycotic drugs (e.g.fluconazole, miconazole, voriconazole). Inducers of CYP2C9 includer ifampicinand carbamazepin.
The gene VKORC1 encodes vitamin K-epoxide reductase (VKORC1),o fw hich several variant alleles have beend escribed. Coumarin anticoagulant derivativest argetsVKORC1. This complex recycles reduced vitamin K, whichisessential for the post-translationalg amma-carboxylation of vitamin K-dependent clotting factorsII(prothrombin),VII, IX,and X, and of proteins C, Sand Z.
The impact of other enzymes polymorphisms, likeG GCX (gamma-glutamyl carboxylase), on coumarin anticoagulant dose finding has beenexamined,but thereare no significant results.
Warfarin
Warfarin is aracemate, with S-warfarinbeing three timesaspotent as R-warfarin. TheS -enantiomeri nw arfarini sp redominantlyr esponsible for the anticoagulant effect.When administered orally, warfarin is completelyabsorbedand 99% is bound to albumin in the plasma. The livera bsorbs the free warfarin where it exerts its anticoagulant effect and is metabolized by several CYP-enzymes.
Ye tfrom aclinical standpoint, R-warfarinisthe most active anticoagulant. This is becauseCYP2C9metabolisesS-warfarin in the first-pass-effect very efficiently.C YP2C9c onvertst he S-enantiomer to 6-and 7-hydroxy-warfarin, whichiseventually excreted in the bile.I nc omparison, CYP1A1, CYP1A2, and CYP3A4 metabolize R-enantiomer into an inactive alcoholmetabolite excreted in the urine.
Patients with eitheraC YP2C9*2 or CYP2C9*3 polymorphismhaveimpaired metabolismofthe more active enantiomer S-warfarinwhen comparedtopatients whoare homozygous for the wild-typea llele CYP2C9*1( 11). The unbound S-warfarin clearance is about two-to three-fold lowerinheterozygouscarriers of the CYP2C9*3 allele and about 10-fold lowerinhomozygous carriers (12).
In vivo,these twoCYP2C9SNPshavebeen associatedwith increased responsiveness to warfarin (13). Aithaletal. (14)compared controls requiring typical warfarin doses to patients whose therapeutic warfarin dose was10.5 mg/weekorless. Theyfound that patients requiring lowdoses of warfarin were moreproneto asupratherapeutic INRatthe timeofwarfarininduction; were almost fourt imesm ore prone to bleed; and were sixt imesm ore likelytohavethe CYP2C9*2 or CYP2C9*3 SNPs. Othersfound that CYP2C9*3 decreasedthe selectivity of CYP2C9 for S-warfarinand that residue 359, the mutated amino acid,was acomponent of the warfarin-binding site.
Patients with one or twoofthese SNPshavereduced warfarin requirementsand an elevatedrisk of an adverseevent by initial warfarin therapy. The CYP2C9SNPsare associated with atwoto three-fold increased risk of bleeding during warfarin induction (15) . This observation suggests thatp harmacogenetics-based warfarin therapywill mainlyaffect the initialwarfarindosage(s). However, because aCYP2C9polymorphism is also associated with adecreased chance to achievestableanticoagulation (16) ,it is possible thatgenotype-steered dosing can alsoplayarole during later stagesofwarfarintherapy.
Recently CYP4F2 genetic variantsw ere associatedw ith a clinically relevant effect on warfarin requirement in the Caucasianp opulation (17) .D ataf rom other ethnicgroups and the roleC YP4F2i na cenocoumarol and phenprocoumon dose requirement are lacking.
Several geneticv ariations of the VKORC1 gene have been found to influencesensitivity to warfarin (18, 19) . Four different heterozygous mutations in the VKORC1 gene were found in individualswith warfarin resistance. Riederetal. (18) investigated the genetic basis of the broadv ariation amongp atients in response to warfarin therapy. Theydeterminedthe VKORC1 haplotype frequenciesi nAfrican-American,E uropean-American and Asian-Americanp opulations, and theyf ound VKORC1 mRNA expression in human livers amples.T heyf ound 28 VKORC1 SNPsi nt he primaryp opulation. Riedere ta l. identified10common (>5%) noncoding VKORC1 single-nucleotide polymorphisms( SNPs) and inferred five major haplotypes, from whichalow-dose haplotypegroup(A) and ahigh-dosehaplotypegroup(B) were derived.
Initial variability in the INR response is mores trongly associatedw ith VKORC1 thanw ith CYP2C9 (20) . Them ean maintenancedosagesofwarfarindiffers significantly amongthe threehaplotypegroupcombinations,atapproximately2.7 mg/ dayf or A/A, 4.9 mg/dayf or A/B,a nd 6.2 mg/dayf or B/B. VKORC1 haplotypeg roups Aa nd Be xplains approximately 25% of the variance in warfarin dose. Moreover, one singlenucleotide polymorphism,such as C1173T in intron 1, appearsto be as informative about coumarinanticoagulant sensitivity as all the five major haplotypes, whichrepresents96% to 99% of the total haplotypes. Asian-Americans have ahigherproportion of group Ahaplotypes,and African-Americans have ahigherproportion of group Bh aplotypes.W adelius et al. ( 21) finds that VKORC1 SNPsc ovaried significantlyw ith warfarin dose, whichexplains 30% of dose variations (22) . Cytochrome P450 2C9 (CYP2C9) explains 12% of variance in warfarin dose (23) . TheVKORC1 C1173 polymorphismisinstrong disequilibrium with VKORC1 promotor1639. In Europeans, guanine (G)isexpressed. In some other ethnic groups, adenine(A) is more common. Aheterozygousorhomozygous adenine (A)significantly reduces VKOR expression comparedwith G/G.The VKORC1 variation p.Trp59Arg ( 24) and Asp36Tyr (25) have beend escribedtoexplain coumarin resistance.
Incorrect dosage,especially during the initial phase of treatment, carriesahigh risk for either severe bleeding or failureto prevent thromboembolism.G enotype-based dose predictions mayenable personalizeddrugtreatment from the start of warfarintherapy (26) .
Acenocoumarol
LikeS-warfarin,S-acenocoumarol is morepotent than R-acenocoumarol and is metabolizedb yC YP2C9 (27) (28) (29) (30) . CYP1A2, 3A4, 2C9 and 2C19 metabolize R-acenocoumarol. An important pharmacokinetic difference betweenwarfarinand acenocoumarol is that S-and R-warfarinhavehalf-lives of approximately 32 and 43 hours, while S-and R-acenocoumarol have half livesof2 and 8h ours. As ar esulto fs lowere limination of the S-enantiomer, R-acenocoumarol is largelyr esponsible for the overall anticoagulant response. Furthermore, R-acenocoumarol is clini- callyt he more important enantiomer because of the very short half-life of S-acenocoumarol (31). Patients with aCYP2C9v ariant allele have ahigherrisk of earlyacenocoumarol overanticoagulation (32, 33) . Patients with the CYP2C9*3, butn ot the CYP2C9*2 variant,a re knownt o requireal ower maintenanced ose of racemic acenocoumarol (34) (35) (36) (37) .The S-acenocoumarol clearanceinaheterozygouscarrier of the CYP2C9*3allele is morethan 15-fold lowerthan in wild-type subjects. This difference betweenCYP2C9*2 and *3 discerns acenocoumarol from warfarin.The S-acenocoumarol plasmahalf-lifeisprolonged in the CYP2C9*1/*3 genotypes.
Theeffect is thatS-acenocoumarol pharmacokineticsisdependentonthe CYP2C9 genotype.Specifically, the presence of the CYP2C9*3a llele impairso ral clearance of the coumarin anticoagulants. Thetime needed to achievestability is mainlyassociatedwith the CYP2C9 genotype.
Thegenotype VKORC1 modifiesthe effect of the CYP2C9 genotype on the anticoagulation status (38) .Inseveral studies, the VKORC1 genotype,r ather thanb yt he CYP2C9 genotype, explains alarger partofthe dose requirement. Severe, over anticoagulation is mostlyassociatedwith the combination of variant alleles of CYP2C9 and VKORC1 (39-41).
Phenprocoumon
Phenprocoumon seemspreferable in poormetabolisers of coumarinanticoagulants (42) .Phenprocoumon has along half-life: it is approximately 172 hours for the more potent S-phenprocoumon enantiomer,a nd approximately 156 hours for R-phenprocoumon. The S-enantiomer is predominantlyresponsible for the anticoagulant effect in phenprocoumon. TheS-7-hydroxylation is the most important metabolising factor (43, 44) .Ye tthe *2 and *3 allele significantly compromisesthe S-7-hydroxylation in a gene-dose-dependent manner. Phenprocoumon metabolismappears to be less influenced by the 2C9 genotypeswhen compared with other coumarin anticoagulants (45, 46) . S-and R-phenprocoumon arep redominantlym etabolisedb yC YP2C9a nd 3A4 (Fig. 1) .
The significant role of the non-polymorphic 3A4inphenpro-coumon metabolism makes it apossibly saferdrugtouse over other coumarina nticoagulants. The oralc learance of S-acenocoumarol is morethan 15-fold lowerinacarrier of the heterozygous *3 genotypecompared with the *1 *1 genotype.The oral clearanceo fS -phenprocoumon is onlym arginally reduced in variant allele carriers (47) . Theclearance of R-phenprocoumon is essentiallyunchanged. About 40% of an oraldose of phenprocoumon is excreted unchanged (48, 49) , whereas warfarin and acenocoumarol are almostc ompletelym etabolised( Table1 ) (50) . Phenprocoumon therefore seemspreferable in poormetabolisers of coumarinanticoagulants.
Finally, likeS -warfarin and S-acenocoumarol,b oth S-and R-phenprocoumon inhibitv itamin Ke poxide reductase (the S-enantiomer being 2-5 times as potent as the R-enantiomer).
The effects of the CYP2C9 polymorphismso nt he pharmacokinetics and anticoagulant response arel eastp ronounced for phenprocoumon,yet the VKORC1 genotype can modifythe effect of the CYP2C9 genotype on phenprocoumon dose requirements. Greater variability in doser equirement is observed by the VKORC1 genotype thanbythe CYP2C9 genotype. Schalekamp et al. showedt hat in patients without aVKORC1 variant allele, carriers of aCYP2C9variant need dosagesthat are nearly30% lowerthan those for CYP2C9*1/*1 patients (51).In patients with aVKORC1 variant allele, differences between carriers of aCYP2C9variant and CYP2C9*1/*1 are statistically insignificant,suggesting that differencesbetween CYP2C9 genotypes mainlyapplytopatients without aVKORC1 variant allele. Carriers with acombination of CYP2C9 variant and VKORC1 variant alleles show as ignificant increase in the risk of severe overanticoagulation, whereas delayed stabilization is mainlyassociatedw ith the CYP2C9 genotype.C arriers of the *3 allele have ahigherrisk of bleeding (52) .From aclinical perspective, the bleeding risk of patients using phenprocoumon should be taken into consideration (53) .
Patients usingphenprocoumon have morestableINR values thanpatients on acenocoumarol and requirefewer monitoring visits (54, 55) . Because of the long half-life time, overanticoagulatedpatients usingphenprocoumon areatgreater risk of major bleedingsdue to the prolongedperiod of overanticoagulation.
Coumarin anticoagulants andNSAIDs drug-drug interactions
CYP2C9 metabolisesseveral drugs(seeabove), especially some NSAIDs, making apharmacokinetic interaction with the coumarin anticoagulants conceivable (56) (57) (58) . The effects of NSAIDs arew elld ocumented. NSAIDs( excluding cyclooxygenase [COX]2-selectiveN SAIDs)i nhibit plateleta ggregation which increases the risk of bleeding (59) .This pharmacodynamic interaction is not reflectedb yac hange in the prothrombin timea s In patients treatedwith acenocoumarol,the risk of overanticoagulation when using CYP2C9 metabolised NSAIDsw as modifiedbyallelic variantsofCYP2C9, especially CYP2C9*3. This wasnot observedwith phenprocoumon. Possibly there were notenough patients included in this study for afirmconclusion.
Patients whohaveavariant CYP2C9 enzyme and useacenocoumarol are at greater risk of INRvalues above 4.9 when concomitant NSAIDs are used (60). Analysis of the variant groups for NSAID userss hows that therei sn od ifference within the wild-typesubgroups, because these patients have the fullcapacity for eliminating drugs.Anincrease in the measuredINRsis seen only in the subgroup of patients with CYP2C9 variantstype *2 or *3 whoa lso use NSAIDs.The capacity of the CYP2C9 variant polymorphisms to hydroxylate substrate drugs is diminished,a nd the administration of twos ubstrate drugs mayh ave pharmacokinetic effects on the elimination on one or both drugs.
Masche et al. investigated the effect of the co-administration of the NSAID lornoxicam on S-and R-phenprocoumon and foundthat it mainlyalters the pharmacokineticsofS-phenprocoumon (61) .
Conclusion
Knowingabout the presenceofboth CYP2C9 and VKORC1 in the patient'sgenotype broadens our insight into the activity of the different coumarinanticoagulants in the individual patient contributing to asafer pharmacotherapy (62) (63) (64) (65) (66) .
The effect of VKORC1 allelic variantsi sr elativelys imilar for all three VKAsand explains 25% of the variance of the response to coumarina nticoagulant therapy. The effect of the CYP2C9*2 and *3 polymorphismsismost prominent for warfarin. Foracenocoumarol,onlyCYP2C9*3 has an effect. Forphenprocoumon, we observe amarginal effect of the CYP2C9 polymorphisms, whichi sp robably limitedt op atients without a VKORC1 variant allele.
Thec ombination of variant VKORC1 and CYP2C9 alleles explains amajor partofthe inter-individual differencesinVKAs dosages (67) . The combination of variant VKORC1 and CYP2C9 allelesincreases the risk of major bleedings. The impact of the combination of the polymorphisms is the greatestin the initialweeks of starting coumarinanticoagulant therapy. Delayedstabilisation is associatedwith having aCYP2C9polymor-phism.The CYP4F2 genetic variant alters the required warfarin dose, datafor acenocoumarol and phenprocoumon arelacking. Race-based differences in warfarin maintenanced ose seems mainlyd ependento nt he linked VKORC1 variants. Although speculative, onecan expectthe same patternfor acenocoumarol and phenprocoumon.
From ac linical perspective, phenprocoumon seemsp referable for therapeutic anticoagulation in the absence of pharmacogenetic testing.Phenprocoumon therapyshows the least risk of delayeddestabilisation compared to warfarin or acenocoumarol. TheeffectsofCYP2C9polymorphismsonthe pharmacokinetics and anticoagulant response areleastpronounced in the caseof phenprocoumon. Patients on phenprocoumonh aveI NR values moreo ften in the therapeutic windowa nd require less control than patients on acenocoumarol. The drug-drug pharmacokinetic interactions with NSAIDsa re the leastp ronounced for phenprocoumon.
Pharmacogenetic testing mayadd to the safety of coumarin anticoagulant therapy. Pharmacoeconomic evaluations of pharmacogenetic testing suggest this is cost-effectivefor acenocoumarol and warfarin (68, 69 
